ALUR Asil keuangan resik Allurion

Exclusive patents and strict FDA control provide Allurion Technologies (ALUR) with high market protection. The company's net income and expenditure balance, which shapes GURU.Markets quotes, demonstrates stability, while the -0.03 indicator confirms the current level. Despite debts and regulatory pressure in the US, the brand maintains its status as a global innovator in non-surgical obesity treatment.

Allurion Technologies (ALUR) profitability is based on high margins from the sale of Elipse non-surgical balloons and recurring payments for digital monitoring. This chart of the company's profits captures daily net income dynamics, allowing investors to assess the quality of liabilities and the actual debt load prior to the publication of SEC quarterly reports to balance the asset's reliability with the startup's growth potential.